Overview

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Status:
Not yet recruiting

Trial end date:
2024-07-15

Target enrollment:

Participant gender:

Summary

This phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as vudalimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Phase:

Phase 2

Details

Lead Sponsor:

Northwestern University

Collaborator:

National Cancer Institute (NCI)

Treatments:

Antibodies
Antibodies, Bispecific
Immunoglobulins